Genius Biotechnologie

Genius Biotechnologies is a French biotechnology company specializing in the development of next-generation cell and gene therapies, with a primary focus on chimeric antigen receptor T-cell (CAR-T) treatments. Spun off from the Institut Curie and Inserm, the company leverages its proprietary Genius platform to engineer immune cells with enhanced precision and efficacy for treating hematological malignancies. The company's technology aims to overcome current limitations in cell therapy manufacturing and delivery, providing more accessible and potent options for patients with refractory cancers. Genius Biotechnologies operates within the vibrant Paris biotech ecosystem, maintaining strong ties to leading academic research institutions to drive its innovation pipeline.